DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

MRI Homepage

Supplemental breast MR superior to ultrasound for screening breast cancer survivors But what about cost-effectiveness?

German researchers find sweet alternative to conventional MR contrast agents Imaging with glucose using 7T MR scanner

Philips to buy EEG technology manufacturer for approximately €32.9 million Company plans to establish new neurology portfolio

MIT and MGH partner to enhance low-quality clinical brain MR images Could have implications for stroke victims, Alzheimer's

Toshiba Medical launches Vantage Titan / Zen 1.5 T MR for quieter, patient-friendly scans Mute sequences use software to cut sound by 99 percent

Michigan cancer center is first to acquire MR linac radiation therapy system Henry Ford is installing the MRIdian Linac from ViewRay

Researchers to undertake largest breast cancer clinical trial in Oklahoma Findings may have practice-changing implications

Pistol mishap damages MR machine in India This is why you don't walk into the MR environment with a firearm

New protocol uses MR-HIFU to release cancer drugs and ablate tumor tissue Research led by Philips and two European universities

CDC report finds Alzheimer's death rate rose by 55 percent from 1999 to 2014 Over five million Americans are living with the disease

ACR responds to European PRAC recommendations on linear gadolinium agents

by Thomas Dworetzky , Contributing Reporter
The American College of Radiology has come out in disagreement with the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency, over its recommendations concerning linear gadolinium-based contrast agents (GBCAs).

The European group raised the alarm concerning the potential risk of gadolinium accumulation in humans, recommending “regulatory actions, including suspension for some marketing authorizations.”

Story Continues Below Advertisement

The (#1 Resource) for Medical Imaging and Peripherals. Call 1-949-273-8000

As a Master Distributor for major brands Barco, Philips, and Sony, we offer custom imaging solutions. With our renowned OEM Solutions and Service/Repair Center, Ampronix is a one-stop shop for HD Medical LCD Displays--Printers--Recorders--4K Cameras



The ACR advised that, “although intracranial gadolinium retention following intravenous GBCA administration has only recently been reported, it has been known for over 10 years that some gadolinium chelates are not completely stable in vivo.”

Based on its review of the findings, the group advised that, “fortunately, there is indisputable evidence that the amount of gadolinium deposited in tissues after a single GBCA dose is incredibly small, and is detectable using only the most sensitive of medical and scientific instrumentation,” — adding that, “although gadolinium accumulation appears to be dose-dependent, there remains no evidence of cellular toxicity, nor is there credible evidence of neurologic sequelae after over 300 million worldwide human doses.”

The PRAC review had found evidence of brain deposits of the agent in “small amounts” after MR body scans “but no signs of harm.”

In its March 10th announcement PRAC advised that the specific agents included:

  • Gadobenic acid, marketed under the trade name MultiHance by Bracco

  • Gadodiamide, sold under the trade name Omniscan by GE Healthcare

  • Gadopentetic acid, marketed as Magnevist by Bayer HealthCare Pharmaceuticals

  • Gadoversetamide, sold as Optimark by Guerbet

Guerbet “concurred” with the PRAC gadolinium recommendations, and in a March 31 statement announced that it had proactively requested a labeling change in the U.S. to Optimark (gadoversetamide) injection, which had been approved by the FDA in August, 2016.

“This change is included in the Pharmacokinetics section (12.3) of the Prescribing Information and notes: Increased signal intensity on non-contrast T1-weighted images within the brain, mainly the globus pallidus and the dentate nucleus, has been observed after multiple administrations of linear (ionic and nonionic) gadolinium-based contrast agents due to gadolinium deposition,” stated the company.

"Guerbet proactively sought this labeling change to ensure that prescribers and patients have all the relevant information clearly available regarding linear GBCAs," said Massimo Carrara, general manager, Guerbet U.S.
  Pages: 1 - 2 >>

MRI Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED